What is the current valuation of the Japan ophthalmic drugs and devices market?

As of 2024, the market valuation was 2.73 USD Billion. Read More

What is the projected market size for the Japan ophthalmic drugs and devices market by 2035?

The market is projected to reach 4.73 USD Billion by 2035. Read More

What is the expected CAGR for the Japan ophthalmic drugs and devices market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 5.14%. Read More

Which segments are included in the Japan ophthalmic drugs and devices market?

The market includes segments such as glaucoma, cataract, retinal disorders, dry eye, and infection. Read More

What were the valuations for the glaucoma segment in 2024 and its projected value in 2035?

The glaucoma segment was valued at 0.82 USD Billion in 2024 and is projected to reach 1.42 USD Billion by 2035. Read More

How does the cataract segment perform in terms of market valuation?

The cataract segment had a valuation of 0.91 USD Billion in 2024, with a projected increase to 1.58 USD Billion by 2035. Read More

What is the market valuation for surgical instruments in the Japan ophthalmic market?

Surgical instruments were valued at 0.55 USD Billion in 2024, with a projected value of 0.95 USD Billion by 2035. Read More

What is the projected market size for contact lenses by 2035?

The contact lenses segment is expected to grow from 0.75 USD Billion in 2024 to 1.25 USD Billion by 2035. Read More

Which end-user segment is expected to show the highest growth in the Japan ophthalmic drugs and devices market?

The hospitals segment, valued at 0.82 USD Billion in 2024, is projected to grow to 1.42 USD Billion by 2035. Read More

Japan Ophthalmic Drugs Devices Market

Q: What are the key players in the Japan ophthalmic drugs and devices market?

Key players include Novartis, Roche, Santen Pharmaceutical, Alcon, Bausch Health, Johnson & Johnson, Merck & Co., AbbVie, and Hoya Corporation. Read More

ID: MRFR/Pharma/51781-HCR

200 Pages

Vikita Thakur

Last Updated: March 28, 2026

Japan Ophthalmic Drugs and Devices Market Research Report By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others) - Growth & Industry Forecast 2025 To 2035

Japan Ophthalmic Drugs Devices Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.14%

2024 Market Size$ 2.73 Billion

2025 Market Size$ 2.91 Billion

2035 Market Size$ 4.73 Billion

Key Players

Novartis

Roche

Santen Pharmaceutical

Alcon

Bausch Health

Johnson & Johnson

Trends

Technological Advancements in Devices
Increased Focus on Preventive Care
Regulatory Support for Innovation

Opportunities

Growing Awareness of Eye Health
Aging Population and Rising Eye Disorders
Regulatory Support and Market Accessibility

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Glaucoma
  2. 4.1.2 Cataract
  3. 4.1.3 Retinal Disorders
  4. 4.1.4 Dry Eye
  5. 4.1.5 Infection
2. 4.2 Healthcare, BY Device Type (USD Billion)
  1. 4.2.1 Surgical Instruments
  2. 4.2.2 Diagnostic Equipment
  3. 4.2.3 Contact Lenses
  4. 4.2.4 Intraocular Lenses
  5. 4.2.5 Ophthalmic Solutions
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Home Care
  4. 4.3.4 Research Institutions
  5. 4.3.5 Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Santen Pharmaceutical (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Alcon (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bausch Health (CA)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Johnson & Johnson (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Hoya Corporation (JP)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 JAPAN MARKET ANALYSIS BY APPLICATION
3. 6.3 JAPAN MARKET ANALYSIS BY DEVICE TYPE
4. 6.4 JAPAN MARKET ANALYSIS BY END USER
5. 6.5 KEY BUYING CRITERIA OF HEALTHCARE
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF HEALTHCARE
8. 6.8 DRIVERS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 SUPPLY / VALUE CHAIN: HEALTHCARE
11. 6.11 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
13. 6.13 HEALTHCARE, BY DEVICE TYPE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY DEVICE TYPE, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY END USER, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY DEVICE TYPE, 2026-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Japan Ophthalmic Drugs Devices Market Segmentation

Japan Ophthalmic Drugs Devices Market By Application (USD Billion, 2026-2035)

Glaucoma
Cataract
Retinal Disorders
Dry Eye
Infection

Japan Ophthalmic Drugs Devices Market By Device Type (USD Billion, 2026-2035)

Surgical Instruments
Diagnostic Equipment
Contact Lenses
Intraocular Lenses
Ophthalmic Solutions

Japan Ophthalmic Drugs Devices Market By End User (USD Billion, 2026-2035)

Hospitals
Clinics
Home Care
Research Institutions
Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”